1781P Health-related quality of life (HRQoL) deterioration-free survival (DetFS) by prostate-specific antigen (PSA) decline in darolutamide (DARO)-treated patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from ARAMIS
Publication
, Conference
Morgans, AK; Sweeney, C; Wallis, C; Halabi, S; Armstrong, AJ; Mohamed, AF; Adorjan, P; Verholen, F; Srinivasan, S; Grimm, M-O
Published in: Annals of Oncology
October 2023
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
October 2023
Volume
34
Start / End Page
S962 / S962
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Morgans, A. K., Sweeney, C., Wallis, C., Halabi, S., Armstrong, A. J., Mohamed, A. F., … Grimm, M.-O. (2023). 1781P Health-related quality of life (HRQoL) deterioration-free survival (DetFS) by prostate-specific antigen (PSA) decline in darolutamide (DARO)-treated patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from ARAMIS. In Annals of Oncology (Vol. 34, pp. S962–S962). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.09.2731
Morgans, A. K., C. Sweeney, C. Wallis, S. Halabi, A. J. Armstrong, A. F. Mohamed, P. Adorjan, F. Verholen, S. Srinivasan, and M. -. O. Grimm. “1781P Health-related quality of life (HRQoL) deterioration-free survival (DetFS) by prostate-specific antigen (PSA) decline in darolutamide (DARO)-treated patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from ARAMIS.” In Annals of Oncology, 34:S962–S962. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.09.2731.
Morgans AK, Sweeney C, Wallis C, Halabi S, Armstrong AJ, Mohamed AF, et al. 1781P Health-related quality of life (HRQoL) deterioration-free survival (DetFS) by prostate-specific antigen (PSA) decline in darolutamide (DARO)-treated patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from ARAMIS. In: Annals of Oncology. Elsevier BV; 2023. p. S962–S962.
Morgans, A. K., et al. “1781P Health-related quality of life (HRQoL) deterioration-free survival (DetFS) by prostate-specific antigen (PSA) decline in darolutamide (DARO)-treated patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from ARAMIS.” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S962–S962. Crossref, doi:10.1016/j.annonc.2023.09.2731.
Morgans AK, Sweeney C, Wallis C, Halabi S, Armstrong AJ, Mohamed AF, Adorjan P, Verholen F, Srinivasan S, Grimm M-O. 1781P Health-related quality of life (HRQoL) deterioration-free survival (DetFS) by prostate-specific antigen (PSA) decline in darolutamide (DARO)-treated patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from ARAMIS. Annals of Oncology. Elsevier BV; 2023. p. S962–S962.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
October 2023
Volume
34
Start / End Page
S962 / S962
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis